Northwest Biotherapeutics Current Valuation vs. Profit Margin
| NWBO Stock | USD 0.27 0.01 3.85% |
For Northwest Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Northwest Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Northwest Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Northwest Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Northwest Biotherapeutics over time as well as its relative position and ranking within its peers.
Northwest |
Northwest Biotherapeutics Profit Margin vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Northwest Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Northwest Biotherapeutics value to that of its competitors to determine the firm's financial worth. Northwest Biotherapeutics is rated top company in current valuation category among its peers. It also is considered to be number one stock in profit margin category among its peers . The ratio of Current Valuation to Profit Margin for Northwest Biotherapeutics is about 19,684,828 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Northwest Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Northwest Biotherapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Northwest Current Valuation vs. Competition
Northwest Biotherapeutics is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 1.99 Billion. Northwest Biotherapeutics totals roughly 1.03 Billion in current valuation claiming about 52% of equities under Health Care industry.
Northwest Profit Margin vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Northwest Biotherapeutics |
| = | 1.03 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Northwest Biotherapeutics |
| = | 52.10 % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Northwest Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Northwest Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Northwest Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Northwest Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Northwest Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
Northwest Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Northwest Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Northwest Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Northwest Biotherapeutics' important profitability drivers and their relationship over time.
Use Northwest Biotherapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Northwest Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Northwest Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Northwest Biotherapeutics Pair Trading
Northwest Biotherapeutics Pair Trading Analysis
The ability to find closely correlated positions to Northwest Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Northwest Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Northwest Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Northwest Biotherapeutics to buy it.
The correlation of Northwest Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Northwest Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Northwest Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Northwest Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Northwest Biotherapeutics position
In addition to having Northwest Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Northwest OTC Stock
To fully project Northwest Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Northwest Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Northwest Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.